Gilead Stock Skyrockets on Patent Win and Game-Changing HIV Therapies
In summary, Gilead’s share price has rallied on a wave of HIV-related breakthroughs, pipeline achievements, and upbeat guidance. With third-quarter results due Oct. 30, investors will be watching for sustained growth. For now, analysts remain generally optimistic: the consensus rating